基于转录组学分析的槐耳提取物抗肝癌作用机制研究  

Transcriptomic analysis of the antitumor mechanism of Trametes robiniophila extract in hepatocellular carcinoma cells

作　　者：何志强 李浩[1] HE Zhiqiang;LI Hao(He patobiliary and Pancreatic Surgery,Yanbian University Hospital,Yanji 133000,China)

机构地区：[1]延边大学附属医院肝胆胰外科,吉林延吉133000

出　　处：《延边大学学报(自然科学版)》2025年第1期44-49,共6页Journal of Yanbian University(Natural Science Edition)

基　　金：吉林省卫生健康科技能力提升项目(2021JC065).

摘　　要：为了探讨槐耳提取物对肝癌细胞HepG2的抑制作用,利用转录组学分析了其作用机制,采用CCK-8实验测试了不同浓度的槐耳提取物对HepG2细胞增殖的影响,利用转录组测序(RNA-Seq)技术检测实验组与对照组的HepG2细胞的mRNA表达,利用GO功能富集分析和KEGG通路富集分析实验组与对照组的肝癌细胞的差异基因的富集功能和富集通路.CCK-8实验表明,槐耳提取物对HepG2细胞具有剂量依赖性抑制作用,IC_(50)值为11.92mg/mL.转录组测序筛选出3855个上调基因和3591个下调基因.GO富集分析显示,差异基因主要涉及细胞周期调控、代谢调控和蛋白质降解等生物过程.KEGG分析表明,槐耳能够显著影响NF-κB、MAPK、Hippo、AMPK等与肿瘤相关的经典信号通路.上述研究表明,槐耳提取物能够通过调控多条信号通路来抑制肝癌细胞增殖、诱导癌细胞凋亡以及抑制癌细胞转移.This study investigates the effects of Trametes robiniophila extract on HepG2 hepatocellular carcinoma cells and its underlying mechanisms using transcriptomic analysis.The CCK-8 assay demonstrated that Trametes robiniophila extract inhibited HepG2 cell proliferation in a dose-dependent manner,with an ICso value of 11.92 mg/mL.RNA sequencing(RNA-Seq)identified 3855 upregulated and 3591 downregulated genes.Gene Ontology(GO)analysis revealed that differentially expressed genes(DEGs)were primarily associated with cell cycle regulation,metabolic processes,and protein degradation.Kyoto Encyclopedia of Genes and Genomes(KEGG)analysis further showed that Trametes robiniophila extract significantly modulated key tumor-associated pathways,including NF-κB,MAPK,Hippo,and AMPK.These findings suggest that Trametes robiniophila extract suppresses tumor cell proliferation,induces apoptosis,and inhibits metastasis by regulating multiple signaling pathways,providing insight into its potential as an antitumor agent.

关 键 词：槐耳提取物 肝细胞癌 作用机制 转录组测序 

分 类 号：R735.7[医药卫生—肿瘤] R285.5[医药卫生—临床医学]